ReDEFINe study - (Rifampicin Dose Finding Study), a double blind randomized control trial phase IIb Clinical Trial, funded by USAID & NIH through PEER Health program (NCT02169882) Hasan Sadikin General Hospital, Bandung, Jawa Barat, Indonesia, 40161
Active Comparator: Rifampicin 450 mg (standard dose)
Experimental: Rifampicin 900 mg per oral
Experimental: Rifampicin 1350 mg per oral
Along with study drug and placebo, patients received other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months. Patients also received dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
Registry Link